Vycor Medical Inc (VYCO) — SEC Filings
Vycor Medical Inc (VYCO) — 9 SEC filings. Latest: 8-K (Mar 31, 2026). Includes 6 10-Q, 2 10-K, 1 8-K.
View Vycor Medical Inc on SEC EDGAR
Overview
Vycor Medical Inc (VYCO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 31, 2026: Vycor Medical Inc. filed an 8-K on March 31, 2026, reporting its financial results and condition for the period ending March 31, 2026. The filing includes financial statements and exhibits, with specific details on operations and financial performance to be found within the attached documents.
Sentiment Summary
Across 9 filings, the sentiment breakdown is: 1 bearish, 7 neutral, 1 mixed. The dominant filing sentiment for Vycor Medical Inc is neutral.
Filing Type Overview
Vycor Medical Inc (VYCO) has filed 1 8-K, 6 10-Q, 2 10-K with the SEC between Apr 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (9)
| Date | Form | Description | Risk |
|---|---|---|---|
| Mar 31, 2026 | 8-K | Vycor Medical Files 8-K for Q1 2026 Results | low |
| Nov 14, 2025 | 10-Q | VYCOR Narrows Losses by 90% Amid Revenue Surge, Going Concern Doubts Persist | high |
| Aug 8, 2025 | 10-Q | Vycor Medical Narrows Q2 Loss to $1K Amid Flat Revenue | high |
| May 15, 2025 | 10-Q | Vycor Medical Inc. Files Q1 2025 10-Q | medium |
| Apr 15, 2025 | 10-K | Vycor Medical Files 2024 10-K | medium |
| Nov 13, 2024 | 10-Q | Vycor Medical Inc. Files Q3 2024 10-Q | low |
| Aug 13, 2024 | 10-Q | Vycor Medical Inc. Files Q2 2024 10-Q Report | medium |
| May 15, 2024 | 10-Q | Vycor Medical Inc. Files 10-Q for Period Ending March 31, 2024 | low |
| Apr 16, 2024 | 10-K | Vycor Medical Inc. Files 2023 Annual Report on Form 10-K | medium |
Risk Profile
Risk Assessment: Of VYCO's 9 recent filings, 2 were flagged as high-risk, 4 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,446,523 |
| Net Income | -$9,740 |
| EPS | $0.00 |
| Cash Position | $64,230 |
Key Executives
- Chief Executive Officer
Industry Context
The medical device industry is characterized by innovation, regulatory hurdles, and intense competition. Companies often require significant capital for research, development, and market penetration. Success hinges on product differentiation, clinical efficacy, and navigating complex reimbursement landscapes.
Top Tags
10-Q (4) · financials (4) · Small Cap (2) · Quarterly Earnings (2) · Related Party Transactions (2) · Medical Instruments (2) · 10-K (2) · Vycor Medical (2) · financial-results (1) · 8-k (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for nine months ended Sep 30, 2025 | $1,446,523 | Increased by 27.6% from $1,134,098 in 2024 |
| Net Loss for nine months ended Sep 30, 2025 | $9,740 | Decreased by 90.3% from $100,463 in 2024 |
| Working Capital Deficiency | $4,152,481 | As of September 30, 2025, indicating significant liquidity issues |
| Related Party Liabilities | $3,645,811 | Included in working capital deficiency as of September 30, 2025 |
| Cash at end of period | $64,230 | As of September 30, 2025, a decrease from $105,648 at beginning of period |
| Preferred Stock Dividends | $324,370 | Paid for the nine months ended September 30, 2025 |
| Weighted Average Shares Outstanding | 33,372,796 | For the nine months ended September 30, 2025 |
| Loss Per Share - basic and diluted | $0.00 | For the three months ended September 30, 2025 |
| Net Loss | $1,000 | for the three months ended June 30, 2025, indicating ongoing unprofitability. |
| Total Revenue | $1,000 | for the six months ended June 30, 2025, showing stagnant top-line performance. |
| Related Party Revenue | $1,000 | for the three months ended June 30, 2025, highlighting dependency on specific entities. |
| Accumulated Deficit | $1,000 | as of June 30, 2025, reflecting significant historical losses. |
| Series C Preferred Stock | $1,000 | balance as of June 30, 2025, indicating stable preferred equity. |
| Quarterly Period | Q1 | Reporting period is the first quarter of 2025. |
| Fiscal Year End | 1231 | The company's fiscal year ends on December 31st. |
Frequently Asked Questions
What are the latest SEC filings for Vycor Medical Inc (VYCO)?
Vycor Medical Inc has 9 recent SEC filings from Apr 2024 to Mar 2026, including 6 10-Q, 2 10-K, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VYCO filings?
Across 9 filings, the sentiment breakdown is: 1 bearish, 7 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vycor Medical Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vycor Medical Inc (VYCO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vycor Medical Inc?
Key financial highlights from Vycor Medical Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VYCO?
The investment thesis for VYCO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vycor Medical Inc?
Key executives identified across Vycor Medical Inc's filings include Chief Executive Officer.
What are the main risk factors for Vycor Medical Inc stock?
Of VYCO's 9 assessed filings, 2 were flagged high-risk, 4 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Vycor Medical Inc?
Forward guidance and predictions for Vycor Medical Inc are extracted from SEC filings as they are enriched.